Business & Finance
Gilead Sciences reports lower net income of USD2.7bn for Q4 2019
5 February 2020 -

Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) disclosed on Tuesday that it recorded a net income of USD2.7bn (USD2.12 per diluted share) for the fourth quarter 2019.

This reflects a decline in earnings when compared with net income of USD3m (USD0.00 per diluted share) for the same period in 2018.

Total revenues of USD5.9bn were generated for the fourth quarter of 2019, up over total revenues of USD5.8bn for the previous fourth quarter.

Research and development (R&D) expenses of USD1.89bn were recorded in Q4 2019, a decrease versus R&D of USD1.95bn in the fourth quarter of the year before.